UNIVERSITY OF MISSOURI-COLUMBIA
Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone
Optimization of a Treatment for Sjögren's Disease Using Aspirin-Triggered Resolvin D1 and Dexamethasone is a funding opportunity from UNIVERSITY OF MISSOURI-COLUMBIA, up to 489587, closing December 31, 2028.
Dec 31, 2028
(884d left)Overview
ABSTRACT Sjögren's disease is an autoimmune condition characterized by chronic inflammation and diminished secretory function of the salivary glands. Although extensive investigation has been done to understand it, causes of and effective treatments for the disease are still unknown. Given the high degree of need and…